Altay Therapeutics

Altay Therapeutics is a biotechnology company developing small molecule drugs that inhibit transcription factors, proteins that regulate gene expression and have traditionally been difficult to target. The company's drug discovery platform identifies novel allosteric sites that emerge through dynamic structural changes in transcription factors, which are then used to design selective small molecule inhibitors for serious, underserved diseases.

The pipeline includes DX5057, an oral small molecule DUX4 inhibitor in development for facioscapulohumeral muscular dystrophy (FSHD), and a STAT3 inhibitor targeting inflammatory diseases and cancer. Additional research and discovery programs in oncology are underway, including an undisclosed program against a transcription factor relevant to sarcomas and prostate cancer. Programs are at various stages, from lead optimization through IND enabling and Phase 1/2a development.

Altay is a clinical-stage biotechnology company serving patients with limited treatment options. The company is led by a team with drug development expertise across medical, toxicology, regulatory, chemistry, and pharmacology functions, supported by scientific advisors and investors. No pricing or packaging information applies to this product.